Furthermore, because PBRM1 is considered not only a key driver gene of ccRCC but also a key regulator of tumor cell-autonomous immune response in ccRCC, the influence of PBRM1 loss on the response to immune checkpoint inhibitors (ICIs) has been investigated [7,12,13]. This evidence concerns the gene PBRM1 and nonpapillary renal cell carcinoma.